NCT01736462View on ClinicalTrials.gov

Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Corneal Endothelial Cell Changes
Interventions
DRUG

Mapracorat

One drop of mapracorat ophthalmic suspension, 3% four times daily, at approximately four hour intervals, for 14 days in both eyes.

Trial Locations (1)

14609

Bausch & Lomb Inc, Rochester

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT01736462 - Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days | Biotech Hunter | Biotech Hunter